Status:
UNKNOWN
Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
Lead Sponsor:
Bital Savir-Baruch
Collaborating Sponsors:
Blue Earth Diagnostics
Conditions:
Cervical Cancer
Endometrial Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
An important part of staging and deciding the method of treatment is knowing areas of how cancer is involved. Diagnostic imaging is often used to determine the location of the cancer using techniques ...
Eligibility Criteria
Inclusion
- GYN cancer (ovarian, endometrial, or cervical) was biopsy-proven and/or schedule for subsequent surgery based on clinical presentation (imaging, markers)
- Age ≥ 18 years.
- Can tolerate 18F-fluciclovine PET/CT exam (can lie on her back for the duration of the scan).
- Ability to understand and the willingness to sign a written informed consent.
Exclusion
- Ongoing systemic therapy for cancer
- Systemic therapy for cancer in the past 3 months
- Inability to tolerate 18F-fluciclovine PET/CT exam
- Pregnant or lactating women
Key Trial Info
Start Date :
November 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03349463
Start Date
November 14 2018
End Date
December 1 2020
Last Update
February 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Loyola University Medical Center
Maywood, Illinois, United States, 60153